Related Experiment Videos
[Atopic eczema: from pathogeny to therapeutics]
1Service de Dermatologie et Phlébologie, Hôpital Saint-Charles, Montpellier.
Annales De Dermatologie Et De Venereologie
|January 1, 1988
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Evaluation expérimentale de l'hydratation et du pouvoir occlusif in vivo et in vitro d'excipients lipophiles et de leurs émulsions phase huile continue.
International journal of cosmetic science·2009
The therapeutic effects of vitamin D3 and its analogues in psoriasis.
Expert opinion on investigational drugs·2005
Differential expression of a human endogenous retrovirus E transmembrane envelope glycoprotein in normal, psoriatic and atopic dermatitis human skin.
The British journal of dermatology·2004
A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
Dermatology (Basel, Switzerland)·2004
[Eosinophilic-like erythema: a clinical subset of Wells' eosinophilic cellulitis responding to antimalarial drugs?].
Annales de dermatologie et de venereologie·2002
2024 guidelines (S3) for the therapeutic management of patients with genital herpes.
Annales de dermatologie et de venereologie·2026
Topical JAK inhibitors in the lichen planus spectrum: a systematic review.
Annales de dermatologie et de venereologie·2026
2024 recommendations for the therapeutic management of anogenital warts.
Annales de dermatologie et de venereologie·2026
Depression and anxiety in visible skin diseases affecting the hands and face: a systematic literature review.
Annales de dermatologie et de venereologie·2026
HER2 inhibitors in the management of HER2-positive extramammary Paget's disease: a literature review.
Annales de dermatologie et de venereologie·2026
Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.
Frontiers in immunology·2026
Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).
Frontiers in immunology·2026